Mirre J. Scholte

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Chimeric antigen receptor-natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands.

Chimeric antigen receptor-natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands.

Journal: Cytotherapy

Published: January 29, 2026

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.

Journal: PharmacoEconomics

Published: November 20, 2025

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma.

Journal: PharmacoEconomics

Published: November 17, 2025

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: September 25, 2025

Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool.

Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART tool.

Journal: PharmacoEconomics

Published: May 29, 2025

Revising EU pharmaceutical legislation: will it foster drug repurposing?

Revising EU pharmaceutical legislation: will it foster drug repurposing?

Journal: Drug discovery today

Published: October 11, 2024

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.

Journal: PharmacoEconomics

Published: April 30, 2024

How health technology assessment can help to address challenges in drug repurposing: a conceptual framework.

How health technology assessment can help to address challenges in drug repurposing: a conceptual framework.

Journal: Drug discovery today

Published: February 02, 2024

A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US.

A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US.

Journal: The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics

Published: January 01, 2024

Care Pathway Analysis to Inform the Earliest Stages of Technology Development: Scoping Oncological Indications in Need of Innovation.

Care Pathway Analysis to Inform the Earliest Stages of Technology Development: Scoping Oncological Indications in Need of Innovation.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: March 22, 2023

Introduction of Minimally Invasive transCervical oEsophagectomy (MICE) according to the IDEAL framework.

Introduction of Minimally Invasive transCervical oEsophagectomy (MICE) according to the IDEAL framework.

Journal: The British journal of surgery

Published: November 12, 2022

Towards early and broad evaluation of innovative surgical devices: integrating evidence synthesis, stakeholder involvement, and health economic modeling into the clinical research stages of the IDEAL framework.

Towards early and broad evaluation of innovative surgical devices: integrating evidence synthesis, stakeholder involvement, and health economic modeling into the clinical research stages of the IDEAL framework.

Journal: BMJ surgery, interventions, & health technologies

Published: April 29, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026